Evidence map›Paper›PMID 25949908›Full record

ArticleOncoimmunology2015

CD8

Benedikt Fritzsching, Joerg Fellenberg, Linda Moskovszky, Zoltan Sápi, Tibor Krenacs, Isidro Machado, Johannes Poeschl, Burkhard Lehner, Miklos Szendrõi, Antonio Llombart Bosch and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 132 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Osteoimmunology in bone malignancies: a symphony with evil.Journal of the National Cancer Center · 2024
    Review
  18. Article
  19. Review
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 6 countries.

Benedikt FritzschingDepartment of Translational Pulmonology; Translational Lung Research Center (TLRC); Member of the German Center for Lung; University of Heidelberg , Heidelberg, Germany ; Divison of Pediatric Pulmonology & Allergy and Cystic Fibrosis Center; Department of Pediatric Oncology, Hematology; Immunology and Pulmonology; University of Heidelberg , Heidelberg, Germany.
Joerg FellenbergDepartment of Orthopedics and Traumatology; University Hospital Heidelberg , Heidelberg, Germany.
Linda Moskovszky1st Department of Pathology and Experimental Cancer Research; Faculty of Medicine, Semmelweis University , Budapest, Hungary.
Zoltan Sápi1st Department of Pathology and Experimental Cancer Research; Faculty of Medicine, Semmelweis University , Budapest, Hungary.
Tibor Krenacs1st Department of Pathology and Experimental Cancer Research; Faculty of Medicine, Semmelweis University , Budapest, Hungary.
Isidro MachadoPathology Department; Instituto Valenciano de Oncologia , Valencia, Spain.
Johannes PoeschlDivision of Neonatology; Department of Pediatrics; University of Heidelberg , Heidelberg, Germany.
Burkhard LehnerDepartment of Orthopedics and Traumatology; University Hospital Heidelberg , Heidelberg, Germany.
Miklos SzendrõiDepartment of Orthopedics; Semmelweis University , Budapest, Hungary.
Antonio Llombart BoschDepartment of Pathology; Valencia University Medical School , Valencia, Spain.
Ludger BerndCenter for Orthopedics and Traumatology; Hospital Bielefeld , Germany.
Monika Csóka2nd Department of Pediatrics; Semmelweis University , Budapest, Hungary.
Gunhild MechtersheimerDepartment of General Pathology; Institute of Pathology; University Hospital Heidelberg , Germany.
Volker EwerbeckDepartment of Orthopedics and Traumatology; University Hospital Heidelberg , Heidelberg, Germany.
Ralf KinscherfInstitute of Anatomy and Cell Biology; Department of Medical Cell Biology; University of Marburg , Marburg, Germany.
Pierre KunzDepartment of Orthopedics and Traumatology; University Hospital Heidelberg , Heidelberg, Germany.
Semmelweis University · HUHeidelberg University · DEUniversity Hospital Heidelberg · DEFundación Instituto Valenciano de Oncología · ESKlinikum Bielefeld · DEPediatrics and Genetics · USPhilipps University of Marburg · DETaipei Institute of Pathology · TWUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma is the most common primary bone tumor characterized by juvenile onset, tumor heterogeneity, and early pulmonary metastasis. Therapeutic improvement stagnates since more than two decades. Unlike major malignancies, biomarkers as prognostic factors at time of diagnosis are missing. Disease rareness hampers study recruitment of patient numbers sufficient to outweigh tumor heterogeneity. Here, we analyzed in a multicenter cohort the osteosarcoma microenvironment to reduce effects of tumor cell heterogeneity. We hypothesized that quantitative ratios of intratumoral CD8

Indexed as

CD8/FOXP3-ratioCD8+ T cellsCONSORT, consolidated standard of reporting trialsCOSS, Cooperative German–Austrian–Swiss Osteosarcoma Study GroupEORTC, the European Organization for Research and Treatment of CancerFFPE, formalin-fixed and paraffin embeddedIDO, Indoleamine 2, 3-dioxygenaseimmunoscoreMAP, methotrexate-cisplatin-doxorubicinosteosarcomaPD-L1, Programmed-death-Ligand-1regulatory T cellsREMARK, reporting recommendations for tumor marker prognostic studiesTIL, tumor infiltrating lymphocyteTNFα, tumornecrosis factor-αTNM-I, tumor, nodes, metastases-immunoTreg, regulatory Tcell.tumor microenvironment

Identifiers

PMID25949908
PMCPMC4404826
OpenAlexW1982789496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.